Ligand Pharmaceuticals Incorporated (LGND) — Analyst outlook / Analyst consensus target is. Based on 17 analyst ratings, the consensus is bullish — 12 Buy, 4 Hold, 1 Sell.
The consensus price target is $248.00 (low: $230.00, high: $275.00), representing an upside of 6.7% from the current price $232.34.
Analysts estimate Earnings Per Share (EPS) of $5.66 and revenue of $0.16B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.22 vs est $5.66 (missed -103.9%). 2025: actual $6.44 vs est $7.58 (missed -15%). Analyst accuracy: 0%.
LGND Stock — 12-Month Price Forecast
$248.00
▲ +6.74% Upside
Average Price Target
Based on 17 Wall Street analysts offering 12-month price targets for Ligand Pharmaceuticals Incorporated, the average price target is $248.00, with a high forecast of $275.00, and a low forecast of $230.00.
The average price target represents a +6.74% change from the last price of $232.34.
Highest Price Target
$275.00
Average Price Target
$248.00
Lowest Price Target
$230.00
LGND Analyst Ratings
Buy
Based on 17 analysts giving stock ratings to Ligand Pharmaceuticals Incorporated in the past 3 months
EPS Estimates — LGND
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.22
vs Est $5.66
▼ 2,670.8% off
2025
Actual $6.44
vs Est $7.58
▼ 17.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — LGND
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.167B
vs Est $0.163B
▲ 2.3% off
2025
Actual $0.268B
vs Est $0.264B
▲ 1.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
